跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/JPRN-jRCT2031220144
JPRN-jRCT2031220144进行中（未招募）2 期

Phase II trial of atezolizumab (MPDL3280A) plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma

Takehito Shukuya0 个研究点目标入组 47 人开始时间: 2022年6月18日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
2 期
状态
进行中（未招募）
发起方
入组人数
47
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable（—）
性别
All

入选标准

  • •(1) Thymic carcinoma diagnosed histologically.
  • •(2) Diagnosed as Masaoka stage III/IVa/IVb ineligible for radical surgery or radiotherapy, or recurrence after radical surgery or radiotherapy.
  • •(3) No history of drug therapy (cytotoxic anticancer drug, immunotherapy, etc.) for thymic carcinoma.
  • •- However, if the subject received postoperative adjuvant chemotherapy after radical surgery or chemoradiotherapy and received cytotoxic anticancer drugs, the subject is eligible if at least 6 months have passed since the last administration of the drug therapy.
  • •(4) Age at the time of enrollment is 20 years or older.
  • •(5) ECOG Performance Status (PS) is 0 - 1 at the time of enrollment.
  • •(6) Patients must have measurable disease according to RECIST version 1.1.
  • •- However, if only a lesion with a history of radiotherapy can be considered as a measurable lesion, the lesion may be considered as a measurable lesion if it shows a clear tendency to enlarge after radiotherapy.
  • •(7) Laboratory tests performed within 14 days prior to registration meet the following criteria (The same day of the week two weeks prior is acceptable based on the registration date. Delay due to national holidays is acceptable).
  • •- Neutrophil count: >=1,500 /mm3
  • •- Hemoglobin: >= 9.0 g/dL
  • •- Platelet count: >=100,000 /mm3
  • •- AST: =<100 IU/L (=<200 IU/L if liver metastases present)
  • •- ALT: =<100 IU/L (=<200 IU/L for liver metastasis)
  • •- Total bilirubin: =<1.5 mg/dL (=<3.0 mg/dL for indirect hyperbilirubinemia)
  • •- Creatinine clearance: >=45 mL/min (estimated by Cockcroft-Gault formula or measured by 24-hour urine storage method. If the estimated value is less than 45 mL/min, the patient is eligible if the measured value by 24-hour urine collection is 45 mL/min or more.)
  • •- SpO2: >=90%.
  • •- PT-INR: =<1.5 (?3.0 if anticoagulation with warfarin is used)
  • •(8) Expected survival of at least 12 weeks.
  • •(9) Patient has received sufficient explanation and understanding of the disease, its symptoms, and the details of this study, and has given written consent to participate in the study.

排除标准

  • •(1) Active multiple primary neoplasms.
  • •- Duplication of carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma that is considered to be cured by local treatment is not included in active multiple primary neoplasms (duplication of carcinoma).
  • •(2) The patient has symptomatic brain metastasis or carcinomatous meningitis.
  • •- If brain metastases are present, the patient is eligible if asymptomatic or if more than 15 days have passed since local treatment and corticosteroids are less than 10 mg/day of prednisolone equivalent.
  • •(3) Patients are eligible if they have undergone local treatment (radiotherapy: within 14 days, major surgery: within 28 days) within the specified number of days prior to enrollment.
  • •- Radiotherapy: 15 days or more, major surgery: 29 days or more
  • •(4) Patient has a local infection requiring drainage or other surgical procedures or an active systemic infection.
  • •(5) Active hepatitis B, hepatitis C, or HIV infection.
  • •- If the patient is HBs antigen negative and HBs antibody or HBc antibody positive, HBV DNA level is measured and the virus level is less than 20 IU/mL (1.3 Log IU/mL), the patient is eligible.
  • •- If the patient is positive for HCV antibody, he/she is excluded.
  • •(6) Patients have interstitial pneumonia that is clearly evident on imaging.
  • •(7) Pleural/pericardial effusions, or ascites requiring treatment.
  • •- Patients with pleural/pericardial effusions, or ascites that do not require continuous drainage or are clinically stable after drainage are eligible.
  • •(8) Patients with autoimmune diseases or with a history of autoimmune diseases requiring corticosteroid therapy.
  • •- However, vitiligo, alopecia, hypothyroidism (if stable with hormone therapy), type 1 diabetes (if stable with hormone therapy), dermatological disease not requiring systemic therapy, inactive disease stable for more than 5 years (requires research administration office confirmation), celiac disease stable with diet therapy only Celiac disease that is stable on diet alone is eligible.
  • •(9) Patients with non-autoimmune diseases requiring continuous systemic administration (oral or intravenous) of corticosteroids at a dose higher than 10 mg/day of prednisolone equivalent, or on immunosuppressive drugs.
  • •(10) Patient has serious complications such as unstable angina pectoris, congestive heart failure, peptic ulcer, cerebral ischemic attack, uncontrolled hypertension, arrhythmia, or diabetes mellitus.
  • •(11) Hypersensitivity to any of the ingredients or additives of carboplatin, paclitaxel, or atezolizumab.
  • •(12) Pregnant women, lactating women, and women with a positive pregnancy test. Men and women who are pregnant, lactating women, and women who have had a positive pregnancy test or who do not intend to use contraception.
  • •(13) Patients who are currently participating in another clinical trial and receiving an investigational drug, or who participated in another clinical trial and received an investigational drug or used an investigational medical device within 8 weeks prior to the first administration of the investigational drug. or patients who have received treatment with a PD-1 pathway inhibitor in the past.
  • •(14) Other patients who are judged to be inappropriate by the investigator or subinvestigator.

研究者

发起方
Takehito Shukuya

相似试验

招募中
2 期
“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients”
2024-519514-31-00Consorzio Oncotech104
进行中（未招募）
1 期
Atezolizumab in Advanced Non-small cell lung cancer with rare histologies
EUCTR2018-002607-34-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)43
进行中（未招募）
1 期
Phase II study to test whether a combination of three drugs—atezolizumab, vinorelbine, and weekly cyclophosphamide—can activate T-cells in patients with a specific type of advanced breast cancer called triple negative breast cancer.
CTIS2024-514031-20-00Istituto Europeo Di Oncologia S.r.l.40
进行中（未招募）
1 期
Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung cancer patientsMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864on-small cell lung cancer (NSCLC)
CTIS2024-514803-33-00Fundacion GECP51
进行中（未招募）
1 期
Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung cancer patientson small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2020-004459-33-ESFundación GECP51